Keyphrases
Heart Failure
79%
Heart Failure with Preserved Ejection Fraction (HFpEF)
45%
Confidence Interval
36%
Coronary Artery Disease
33%
Patients with Heart Failure
33%
ST-elevation Myocardial Infarction (STEMI)
32%
Metformin
27%
Type 2 Diabetes Mellitus (T2DM)
27%
Left Ventricular Remodeling
21%
Desmosine
21%
All-cause Mortality
19%
Left Ventricular Hypertrophy
18%
Placebo
18%
Meta-analysis
18%
Hazard Ratio
16%
Dilated Cardiomyopathy
15%
Diabetes
15%
Hypertension
14%
Late Gadolinium Enhancement
14%
Inflammation
14%
Acute ST-segment Elevation Myocardial Infarction
14%
Echocardiography
14%
Pathophysiology
14%
Chronic Heart Failure
13%
Beta-blockers
13%
Incremental Prognostic Value
13%
Prognostic Significance
13%
Odds Ratio
13%
Endothelial Dysfunction
13%
Patients with Diabetes
12%
Heart Failure Treatment
12%
Cardiac Magnetic Resonance Imaging (cMRI)
12%
Ejection Fraction
12%
Major Adverse Cardiovascular Events
12%
Electronic Health Records
11%
Exercise-based Cardiac Rehabilitation
11%
Heart Disease Diagnosis
11%
Type 2 Diabetic Patients
11%
Intramyocardial Hemorrhage
11%
Scotland
11%
Elastin
11%
Dapagliflozin
10%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
10%
Ruptured Abdominal Aortic Aneurysm (rAAA)
10%
Survivors
10%
Systematic Meta-analysis
9%
Cardiovascular Disease
9%
Cardiovascular Risk
9%
Genome-wide Association Analysis
9%
Tayside
9%
Medicine and Dentistry
Congestive Heart Failure
100%
ST Segment Elevation Myocardial Infarction
32%
Cardiovascular Disease
30%
Coronary Artery Disease
25%
Cardiac Magnetic Resonance Imaging
25%
Maturity Onset Diabetes of the Young
23%
Biological Marker
22%
Glycon
21%
Heart Failure with Preserved Ejection Fraction
19%
Myocardial Infarction
18%
Ejection Fraction
17%
Diabetes
17%
Heart Failure with Reduced Ejection Fraction
16%
Echocardiography
16%
Left Ventricular Hypertrophy
15%
Gadolinium
14%
Placebo
14%
Meta-Analysis
14%
Infarction
14%
Systematic Review
13%
Ischemic Heart Disease
13%
Cardiovascular System
13%
Pathophysiology
12%
Heart Ventricle Remodeling
12%
Desmosine
12%
Electronic Health Record
11%
Hazard Ratio
11%
Endothelial Dysfunction
9%
Patient with Diabetes
9%
Cohort Analysis
9%
Dilated Cardiomyopathy
9%
Bleeding
9%
Heart Rehabilitation
9%
Abdominal Aortic Aneurysm
9%
Aneurysm
9%
Early Diagnosis
9%
Disease
8%
Obstruction
8%
Genome Wide Association Study
8%
Heart Left Ventricle Ejection Fraction
8%
Atrial Fibrillation
8%
Odds Ratio
7%
Patient with Type 2 Diabetes
7%
Elastin
7%
Mendelian Randomization Analysis
7%
Coronary Angiography
7%
Cardiovascular Effect
7%
Loop Diuretic Agent
6%
Diabetes Mellitus
6%
Adipose Tissue
6%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
93%
ST Segment Elevation Myocardial Infarction
34%
Cardiovascular Disease
26%
Metformin
21%
Placebo
21%
Heart Infarction
21%
Biological Marker
19%
Non Insulin Dependent Diabetes Mellitus
19%
Heart Ventricle Remodeling
19%
Heart Failure with Reduced Ejection Fraction
18%
Inflammation
15%
Desmosine
15%
Bleeding
13%
Heart Left Ventricle Hypertrophy
13%
Coronary Artery Disease
13%
Pathophysiology
13%
Endothelial Dysfunction
12%
Infarction
12%
Heart Failure with Preserved Ejection Fraction
12%
Cohort Study
11%
Disease
10%
Elastin
10%
Cardiovascular Risk
10%
Abdominal Aortic Aneurysm
10%
Dapagliflozin
10%
Obstruction
9%
Loop Diuretic Agent
9%
Diabetes Mellitus
9%
All Cause Mortality
9%
Aneurysm
9%
Randomized Controlled Trial
9%
Ischemic Heart Disease
7%
Cause of Death
7%
Atrial Fibrillation
7%
Beta Adrenergic Receptor Blocking Agent
7%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Cotransporter
6%
Adverse Event
6%
Diabetic Cardiomyopathy
6%
Acute Heart Infarction
6%
Diverticulosis
6%
Diverticulitis
6%
Nicorandil
6%
Genetic Risk
5%